Chief Financial Officer
Matthew's career includes 20 years of Wall Street and corporate leadership experience as a sell-side analyst and investor relations and corporate communications professional within small-to-large cap biotechnology companies. In these roles, he combined the scientific, financial and strategic planning, and investor and communications efforts to help companies navigate through corporate, clinical, regulatory and commercial development and equity and debt financings. He most recently served as head of corporate affairs, communications and investor relations at Voyager Therapeutics, and in similar roles at Shire Plc, Synageva BioPharma and Vertex Pharmaceuticals. On Wall Street, as a biotechnology sell-side analyst at Lazard Capital Markets and Leerink Swann, among others, Matt covered small to large cap biotechnology companies and analyzed several blockbuster drug launches across multiple therapeutic areas and launched several IPOs. Matt received a Bachelor of Science in Biology from Syracuse University and a Master of Business Administration from the D’Amore-McKim School of Business at Northeastern University.